Published in Cancer Treat Rep on November 01, 1978
Active immunotherapy for acute lymphoblastic leukaemia. Lancet (1969) 13.03
Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells. Br J Cancer (1969) 2.96
The need of a physiologic and pathophysiologic definition of stress. Biomed Pharmacother (2000) 1.93
Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst (1990) 1.81
Approaches to the immunological treatment of cancer in man. Br Med J (1969) 1.76
Acute lymphoblastic leukaemia treated with a combination of prednisone, vincristine, and rubidomycin. Value of pathogen-free rooms. Lancet (1967) 1.65
Histopathologic sequence of events in adult mice undergoing lethal graft-versus-host reaction developed across H-2 and/or non-H-2 histocompatibility barriers. Am J Pathol (1979) 1.62
Extensive histological and cytological survey of patients with acute leukaemia in "complete remission". Br Med J (1966) 1.57
Polyphenols: do they play a role in the prevention of human pathologies? Biomed Pharmacother (2002) 1.57
Immunological treatment of leukaemias. Br Med J (1970) 1.47
New antigens in human leukaemic cells and antibody in the serum of leukaemic patients. Lancet (1967) 1.42
Effect of physiologic vs UV pathogenic stress on immunity reactions and tolerance, via immunocyte traffic and homing. Biomed Pharmacother (2000) 1.40
Hypothetical reasons of the HIV1-AIDS "tritherapy" failure. A challenging model. Biomed Pharmacother (1997) 1.37
The two varieties of lymphoid tissue "reticulosarcomas", histiocytic and histioblastic types. Br J Cancer (1970) 1.36
Bone marrow graft in man after conditioning by antilymphocytic serum. Br Med J (1970) 1.32
[Demonstration of the efficacy of active immunotherapy in human acute lymphoblastic leukemia]. Rev Fr Etud Clin Biol (1968) 1.27
Active immunotherapy. Adv Cancer Res (1971) 1.22
The role of immunology in the treatment of leukemias and hematosarcomas. Cancer Res (1967) 1.21
Attempts at immunotherapy of 100 patients with acute lymphoid leukemia: some factors influencing results. Natl Cancer Inst Monogr (1972) 1.20
Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res (1965) 1.19
Phase I pharmacologic study of a new Vinca alkaloid: navelbine. Cancer Lett (1985) 1.13
I. Arginine. Biomed Pharmacother (2002) 1.11
II. Glutamine and glutamate. Biomed Pharmacother (2002) 1.09
Establishment and characterization of a new human eosinophilic leukemia cell line. Blood (1985) 1.08
An overview of the 1978 international meeting on comparative therapeutic trials. Biomedicine (1978) 1.08
[Active immunotherapy of L 1210 leukemia given after the graft of the tumor]. Rev Fr Etud Clin Biol (1968) 1.08
Seasonal modulation of the circadian time structure of circulating T and natural killer lymphocyte subsets from healthy subjects. J Clin Invest (1988) 1.08
T and B lymphocyte markers on the neoplastic cell of 20 patients with acute and 10 patients with chronic lymphoid leukemia. Biomedicine (1974) 1.07
Nonspecific macrophage activation by systemic adjuvants. Evaluation by lysosomal enzyme and in vitro tumoricidal activities. Int Arch Allergy Appl Immunol (1976) 1.06
Inhibition of human monocyte TNF production by adenosine receptor agonists. Life Sci (1993) 1.05
A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP). Biomed Pharmacother (1986) 1.04
Attempted adoptive immunotherapy of acute leukaemia by leucocyte transfusions. Lancet (1966) 1.02
Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther (1994) 1.01
Large-amplitude circadian rhythm in helper:suppressor ratio of peripheral blood lymphocytes. Lancet (1983) 1.00
[Chemotherapy of L1210 leukemia: comparison of 7 drugs given either continuously for 20 days, or in a single massive dose, early or late]. Rev Fr Etud Clin Biol (1968) 1.00
[Spleen reactivity after BCG treatement: test and strain dependency of the response]. Ann Immunol (Paris) (1977) 1.00
[Acute leukemia and various hematosarcomas. Trial treatment with a second derivative of podophyllotoxin (4-demethyl-epipodophyllotoxin beta D ethylidene glucoside VP 16213 or EPE)]. Nouv Presse Med (1974) 0.99
Remission induction with Poly IC in patients with acute lymphoblastic leukaemia (preliminary results). Rev Eur Etud Clin Biol (1970) 0.98
Degree of bronchial metaplasia in heavy smokers and its regression after treatment with a retinoid. Lancet (1982) 0.98
Immunoprecipitation of insulin receptors by antibodies against Class 1 antigens of the murine H-2 major histocompatibility complex. FEBS Lett (1983) 0.97
[Therapeutic trials in various hematosarcomas with 4-demethylepipo=dophyllotoxin-beta D thenylidene glucoside (VM 26 or EPT)]. Nouv Presse Med (1974) 0.97
Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study. Cancer Treat Rep (1982) 0.96
White blood cell transfusions. Isr J Med Sci (1965) 0.96
Clinical examination of drugs, a scientific and ethical challenge. Biomedicine (1973) 0.95
[Hematologic resuscitation. II. Correction of severe leukocyte and immune globulin disorders. The bone marrow graft]. Presse Med (1966) 0.95
Methoxy-9-ellipticine lactate. 3. Clinical screening: its action in acute myeloblastic leukaemia. Rev Eur Etud Clin Biol (1970) 0.95
[Local elective immunotherapy of L 1210 ascitic leukemia. Analysis of factors of its efficacy]. Eur J Cancer (1968) 0.94
The failure of HAART to cure the HIV-1/AIDS complex. Suggestions to add integrase inhibitors as complementary virostatics, and to replace their continuous long combination applications by short sequences differing by drug rotations. Biomed Pharmacother (2001) 0.94
An experimental screening for "systemic adjuvants of immunity" applicable in cancer immunotherapy. Cancer Res (1973) 0.94
Importance of age and methotrexate dosage: prognosis in children and young adults with high-grade osteosarcomas. Biomed Pharmacother (1988) 0.93
Effects of interleukin-6 on cytochrome P450-dependent mixed-function oxidases in the rat. Biochem Pharmacol (1992) 0.93
Efficacy of and errors in randomized multicenter trials. A review of 230 clinical trials. Biomed Pharmacother (1983) 0.92
Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice. Cancer Res (1989) 0.92
[Angioimmunoblastic adenopathies]. Nouv Presse Med (1976) 0.92
Vaccination against spontaneous abortion in mice. J Reprod Immunol (1983) 0.92
Powerful new inhibitor of murine leukaemia and sarcoma viruses. Nature (1970) 0.92
Interleukin-1 synthesis and activity in aged mice. Mech Ageing Dev (1984) 0.91
[Treatment of acute lymphoblastic leukemia during a remission by irradiation of the central nervous system and subsequent administration of 8 chemotherapeutic agents]. Sem Hop (1966) 0.91
[Revelation of leukemigenic virus by means of hematopoietic chimerism. Allogenic chimerism in mice]. C R Acad Sci Hebd Seances Acad Sci D (1966) 0.91
[A new combination of methotrexate and folinic acid for cancer treatment (acute leukemia and solid tumors)]. Presse Med (1969) 0.91
Newborn blood can engraft adult mice without inducing graft-versus-host disease across non H-2 antigens. Blood (1996) 0.90
Bone marrow transplantation in man. Transplant Proc (1969) 0.90
Dichloromethylene diphosphonate (Cl2MDP) reduces natural killer (NK) cell activity in mice. Metab Bone Dis Relat Res (1984) 0.89
[Use of a steady-flow blood cell separator for the separation of blood lymphocytes]. Nouv Rev Fr Hematol (1969) 0.89
Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity. J Clin Oncol (1990) 0.89
Histologic reactions of the thymus, spleen, liver and lymph nodes to intravenous and subcutaneous BCG injections. Biomedicine (1975) 0.89
Pathogen-free isolation unit--three years' experience. Br Med J (1969) 0.88
Chimeric peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity: application in antiviral vaccination. J Immunol (1997) 0.88
[Fibrinogenopenia syndrome during acute leukemia. Determining role of leukemic cells. "In vitro" study of their fibrinolytic capacity]. Rev Fr Etud Clin Biol (1966) 0.88
A lymphocyte-inhibiting factor (chalone?) extracted from thymus: immunosuppressive effects. Natl Cancer Inst Monogr (1973) 0.88
Involvement of IFN-gamma and transforming growth factor-beta in graft-vs-host reaction-associated immunosuppression. J Immunol (1993) 0.87
T lymphocyte specificity of a lymphocyte-inhibiting factor (chalone) extracted from the thymus. Eur J Immunol (1973) 0.87
Immunologic consequences of vaccination against abortion in mice. J Immunol (1985) 0.87
When should the immune clock be reset? From circadian pharmacodynamics to temporally optimized drug delivery. Ann N Y Acad Sci (1991) 0.86
Mismatching for minor histocompatibility antigens in bone marrow transplantation: consequences for the development and control of severe graft-versus-host disease. Transplant Proc (1979) 0.86
Bone marrow graft in man after conditioning by antilymphocytic serum. Transplant Proc (1971) 0.86
Release of interleukin I and low-molecular-weight lymphocyte-activating factors by rat peritoneal macrophages and its enhancement by acute non-specific inflammatory processes. Br J Exp Pathol (1985) 0.86
Are the neoantigens induced by chemical carcinogens or by leukaemogenic viruses particular to cancer cells? Transplant Proc (1969) 0.86
Fas-mediated liver damage in MRL hemopoietic chimeras undergoing lpr-mediated graft-versus-host disease. J Immunol (1997) 0.85
Immune manipulation by BCG administered before or after cyclophosphamide for chemo-immunotherapy of L1210 leukaemia. Eur J Cancer (1974) 0.85
Modifications of host defence mechanisms by an acute non-immunological inflammatory reaction. Br J Exp Pathol (1985) 0.85
Some effects of a partially purified lymphocyte-inhibiting factor from calf thymus. Transplantation (1972) 0.85
Clinical significance and prognostic value of the T-B immunological classification of human primary acute lymphoid leukaemias. Lancet (1977) 0.85
Inhibition of graft-versus-host reaction by preincubation of the graft with a thymic extract (lymphocyte chalone). Transplantation (1973) 0.85
Parameters involved in the induction and abrogation of the lethal graft-versus-host reaction directed against non-H-2 antigens. Immunol Rev (1985) 0.85
[Trial treatment of chronic myeloid leukemia with 3 new chemotherapeutic agents: dibromomannitol, hydroxyurea and desacetamidocolchicine]. Sem Hop (1966) 0.84
Immunogenetic studies of spontaneous abortion in mice. Preimmunization of females with allogeneic cells. J Immunol (1985) 0.84
Non-Hodgkin's malignant lymphomata in adults: chemo-radiotherapy in stages III and IV. Br J Cancer Suppl (1975) 0.84